Galmed Pharmaceuticals (GLMD) Research & Development (2013 - 2025)

Galmed Pharmaceuticals' Research & Development history runs 13 years deep, the most recent figure standing at $2.1 million for Q4 2025.

• In Q4 2025, Research & Development rose 95.52% year-over-year to $2.1 million; the TTM figure through Dec 2025 stood at $4.9 million (up 63.61% YoY), while the FY2025 annual figure was $4.9 million, up 63.61% from the prior year.
• Research & Development was $2.1 million for Q4 2025 at Galmed Pharmaceuticals, up from $1.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $7.4 million in Q1 2021 to a low of $170000.0 in Q1 2022.
• Historically, Research & Development has averaged $2.4 million across 5 years, with a median of $1.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Research & Development sank 97.7% in 2022, then jumped 537.06% in 2023.
• A 5-year view of Research & Development shows it stood at $6.3 million in 2021, then sank by 78.0% to $1.4 million in 2022, then fell by 18.65% to $1.1 million in 2023, then decreased by 4.37% to $1.1 million in 2024, then surged by 95.52% to $2.1 million in 2025.
• The last three Research & Development figures came in at $2.1 million (Q4 2025), $1.1 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.